New Delhi: The National Technical Advisory Group on Immunization (NTAGI) on Friday approved Serum Institute of India’s Covid-19 vaccine Covovax for the 12-17 age group.
The government panel decided to include Covovax in India’s immunisation drive against Covid-19.
Earlier, the Drugs Controller General of India (DCGI) had approved Covovax for restricted use in emergency situations in adults on December 28 and in children in the 12-17 age group, subject to certain conditions,
India’s vaccination drive for children between the ages of 12 and 14 years began from March 16 with Biological E’s Corbevax.